Orca Energy Group (ORCB) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
14 Apr, 2026Executive summary
Revenue rose 51% in Q4 2024 and 1% for the full year compared to prior periods, but some Songas volumes post-July 2024 were not recognized as revenue due to contract disputes.
Net loss attributable to shareholders was $21.6 million for 2024, compared to net income of $7.0 million in 2023, driven by asset impairment and litigation loss allowances.
Gas delivered and sold declined 3% in Q4 and 15% for the year, mainly due to increased hydro power generation and the Songas Power Plant shutdown.
The company faces significant uncertainty regarding the extension of its Songo Songo Development License, set to expire in October 2026.
Financial highlights
Q4 2024 revenue: $36.9 million (up 51% YoY); full-year revenue: $111.6 million (up 1% YoY).
Net loss for 2024: $21.6 million vs. net income of $7.0 million in 2023.
Net cash flows from operating activities fell 37% in Q4 and 44% for the year.
Capital expenditures surged 620% in Q4 and 240% for the year, mainly due to well workover programs.
Working capital at year-end: $21.9 million (down from $67.3 million); cash and equivalents: $90.1 million.
Outlook and guidance
Forecasts 2025 average Additional Gas sales of 70-72 MMcfd, about 4% lower than 2024.
Capital allocation for 2025 will be minimal, limited to essential safety and maintenance due to license uncertainty.
Latest events from Orca Energy Group
- Net income soared 1,786% in Q2 2025 as TANESCO arrears were collected and industrial demand surged.ORCB
Q2 202514 Apr 2026 - Revenue up 2%, net income down 89%; license and legal risks remain significant.ORCB
Q1 202514 Apr 2026 - Revenue fell 9% and net income surged 715% in Q3 amid major contract and operational disputes.ORCB
Q3 202414 Apr 2026 - Revenue and net income fell sharply amid lower gas sales and regulatory disputes in Tanzania.ORCB
Q2 202414 Apr 2026 - Net income soared 834% in Q3 2025, but regulatory and legal risks remain elevated.ORCB
Q3 202514 Apr 2026